Dr. Andrea Cubitt, (CEO and Co-Founder Dionysus), brings a proven track record with three successful exits in the startup environment building high value new companies.
- She is a seasoned executive with extensive commercial, business, biotechnology, intellectual property, and regulatory experience in bringing new technologies to the market.
- She has a deep scientific knowledge in biology and immunology, comprehensive understanding of preclinical, clinical, and regulatory requirements for FDA approval of novel diagnostic and therapeutic approaches.
- Is highly skilled and experienced and very familiar with navigating crowded intellectual property landscapes and securing commercially meaningful IP. Including building high value IP franchises.
After completing a post-doctoral fellowship at Cornell Medical Center, Andrea started her professional career at the Howard Hughes Medical Institute at the University of California, San Diego where her work formed part of the research recognized by Nobel Prize for Chemistry awarded to Roger Tsien in 2008. She left Academia to commercialize this technology at Aurora Biosciences Corporation, which was subsequently acquired by Vertex Pharmaceuticals. Over the following years she worked at a variety of biotechnology companies with increasing roles and responsibilities. In 2005, she co-founded AnaptysBio, INC, (IPO 2017) where she was instrumental in the development of the initial business plan and intellectual property strategies.
She has spent much of her career bringing groundbreaking new technologies, taking bench research to commercialization with multiple successful exits. As such, she has a successful track record of raising funds from seed to institutional investors and strategic partners.
